|
Monday, May 10, 2010
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
Special PCCI Session
Today's Funding Model
Date:
Time:
Location:
Host: |
May 10, 2010
6:00 pm Networking, 7:00 pm Dinner, 8:15 pm Roundtable and Discussion
Embassy Suites Hotel, Chesterbrook, PA
Pharmaceutical Consulting Consortium International Inc. |
About
|
PCCI's May Roundtable will look at the state of today's funding model. The goal is to come up with new thinking from key stakeholders aimed at pointing it in a more useful direction. The discussion will be led by an experienced panel of experts and leaders in the field (see below).
Because of "de-risking", the life science development projects that stand the best chance of getting funded are arguably those that recycle old therapeutics (because they are a "surer" thing). Not that the process isn't already flawed, because in many cases the concept of de-risking tends to leave the truly innovative technologies with little chance of seeing the light of day.
In effect, the current model tends to significantly limit viability for early-stage companies at the bottom of the funding chain ($500,000 to $2MM) for a variety of reasons, not the least of which have been budget cuts and a lagging economy. These early-stage technology companies are also under enormous pressure due to a lack of follow-on funding. The next leg up ($2MM to $12MM) is almost non-existent. Also, the more typical VC rounds are being squeezed by pharma's need to see later-stage evidence of the potential for successful commercialization.
So what can be done? Some variations on that theme will be presented and discussed at the May PCCI dinner.
Speakers
|
- Elaine Jones, Executive Director Venture Capital, Pfizer, will moderate the roundtable.
- Congresswoman, the Honorable Allyson Y. Schwartz, will approach the problem from the Federal Government's point of view.
- Brenda Gavin, founding partner of Quaker BioVentures, and recently honored with Pennsylvania BIO's Hubert J. P. Schoemaker's Leadership Award, will represent venture capital's perspective.
- Chris Cashman, CEO, Protez Pharmaceuticals, will speak to the issue from his involvement in the recent sale of Protez to Novartis.
- Wayne Barz, Manager, Entrepreneurial Programs, Benjamin Franklin Technology Partners, Lehigh, will represent the early-stage end of the spectrum
- Representing big pharma will be Carol Ashe from GSK's SR One and Bob Zivin from J&J's Corporate Office of Science & Technology.
Full Bios available!
Too read the full bios of the speakers listed above please click here
Meeting Details
|
Cost of dinner and presentation:
Members: $40,
Non-members: $60.
Seating will be limited to 120 people. Parking is free.
The meeting will be webcast. Those who cannot join the meeting can still participate. Webcast registration will be $20. A password will be given.
More details, including a formal announcement and registration information, will be made available in the coming weeks, mark your calendar now: May 10, 2010, 6:00 pm!
Program:
|
6:00 - Networking
7:00 - Dinner
8:15 - Roundtable and Discussion
<Top of the page>
|
 |
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
